Cingulate Announces Adjournment of Special Meeting
Cingulate Inc. (NASDAQ:CING) has adjourned its Special Meeting of Stockholders due to insufficient quorum. The meeting is rescheduled for August 28, 2024, at 11:00 a.m. Central Time. The company's Board of Directors believes all proposals in the proxy statement are in the best interests of stockholders and recommends voting FOR all agenda items. The record date for the Special Meeting remains June 28, 2024. Stockholders can vote live by calling 1-800-652-8683 or online at www.envisionreports.com/CING-SP. Cingulate is a biopharmaceutical company using its Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products.
Cingulate Inc. (NASDAQ:CING) ha rinviato la sua Assemblea Straordinaria degli Azionisti a causa di un numero insufficiente di partecipanti. L'incontro è stato riprogrammato per il 28 agosto 2024, alle 11:00 ora centrale. Il Consiglio di Amministrazione dell'azienda ritiene che tutte le proposte contenute nella lettera di delega siano nel miglior interesse degli azionisti e raccomanda di votare FOR su tutti i punti all'ordine del giorno. La data di registrazione per l'Assemblea Straordinaria rimane il 28 giugno 2024. Gli azionisti possono votare dal vivo chiamando il numero 1-800-652-8683 o online su www.envisionreports.com/CING-SP. Cingulate è un'azienda biofarmaceutica che utilizza la sua piattaforma di rilascio temporizzato di precisione™ (PTR™) per sviluppare prodotti farmaceutici di nuova generazione.
Cingulate Inc. (NASDAQ:CING) ha aplazado su Junta Especial de Accionistas debido a un quórum insuficiente. La reunión está reprogramada para el 28 de agosto de 2024, a las 11:00 a.m. Hora Central. La Junta Directiva de la compañía cree que todas las propuestas en el documento de poder son en el mejor interés de los accionistas y recomienda votar A FAVOR de todos los puntos de la agenda. La fecha de registro para la Junta Especial sigue siendo el 28 de junio de 2024. Los accionistas pueden votar en vivo llamando al 1-800-652-8683 o en línea en www.envisionreports.com/CING-SP. Cingulate es una empresa biofarmacéutica que utiliza su plataforma de entrega de medicamentos de Liberación Temporizada de Precisión™ (PTR™) para desarrollar productos farmacéuticos de próxima generación.
Cingulate Inc. (NASDAQ:CING)는 주주 특별 회의를 연기했습니다 상정된 안건의 재적 인원이 부족하여. 회의는 2024년 8월 28일 오전 11:00 중앙 표준시에 다시 예정되었습니다. 회사의 이사회는 위임장 명세서의 모든 제안이 주주의 최선의 이익에 부합한다고 생각하며 모든 안건에 대해 찬성 투표를 권장합니다. 특별 회의의 기준일은 2024년 6월 28일입니다. 주주는 1-800-652-8683로 전화하거나 www.envisionreports.com/CING-SP에서 온라인으로 실시간 투표할 수 있습니다. Cingulate는 다음 세대 제약 제품을 개발하기 위해 정밀 타이밍 방출™(PTR™) 약물 전달 플랫폼을 사용하는 생물 제약 회사입니다.
Cingulate Inc. (NASDAQ:CING) a reporté sa Réunion Extraordinaire des Actionnaires en raison d'un quorum insuffisant. La réunion est reprogrammée pour le 28 août 2024 à 11h00 heure centrale. Le Conseil d'Administration de l'entreprise estime que toutes les propositions dans le document de procuration sont dans le meilleur intérêt des actionnaires et recommande de voter POUR tous les points à l'ordre du jour. La date de référence pour la Réunion Extraordinaire reste le 28 juin 2024. Les actionnaires peuvent voter en direct en appelant le 1-800-652-8683 ou en ligne sur www.envisionreports.com/CING-SP. Cingulate est une entreprise biopharmaceutique qui utilise sa plateforme de délivrance de médicaments à libération chronométrée de précision™ (PTR™) pour développer des produits pharmaceutiques de prochaine génération.
Cingulate Inc. (NASDAQ:CING) hat seine Sonderversammlung der Aktionäre vertagt, da nicht genügend Teilnehmer vorhanden waren. Die Sitzung wurde neu terminiert auf den 28. August 2024, um 11:00 Uhr Central Time. Der Vorstand des Unternehmens ist der Ansicht, dass alle Vorschläge im Stimmrechtsunterlagen im besten Interesse der Aktionäre sind und empfiehlt, für alle Tagesordnungspunkte zu stimmen. Das Stichtagsdatum für die Sonderversammlung bleibt der 28. Juni 2024. Aktionäre können live abstimmen, indem sie 1-800-652-8683 anrufen oder online unter www.envisionreports.com/CING-SP abstimmen. Cingulate ist ein biopharmazeutisches Unternehmen, das seine Plattform für zeitgesteuerte Freisetzung™ (PTR™) zur Entwicklung von Pharmazieprodukten der nächsten Generation nutzt.
- None.
- None.
KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.
At this time, there are not present, by remote communication or by proxy, a sufficient number of shares of the Company’s common stock to constitute a quorum. The Company’s Board of Directors continues to believe that that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company’s stockholders to consider and act upon. Therefore, the Company adjourned the Special Meeting.
The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024, at the following url: www.meetnow.global/MCZZ4DG. The record date for the Special Meeting is June 28, 2024.
Special Meeting of Stockholders of Cingulate Inc.
The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024, at the following url: www.meetnow.global/MCZZ4DG. The Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda.
Stockholders may cast their vote live by calling toll free at 1-800-652-8683 or online by going to www.envisionreports.com/CING-SP.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City.
Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301
Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200
FAQ
When is the adjourned Special Meeting of Stockholders for Cingulate (CINGW) scheduled?
Why did Cingulate (CINGW) adjourn its Special Meeting of Stockholders?
What is the record date for Cingulate's (CINGW) Special Meeting of Stockholders?
How can stockholders vote for Cingulate's (CINGW) Special Meeting?
